Opinion -: Therapeutic vaccines against HIV need international partnerships

被引：29

作者：

Autran, B ^{[1
]}

Debré, P

Walker, B

Katlama, C

机构：

[1] CHU Pitie Salpetriere, Lab Immunol Cellulaire, Serv Malad Infect, F-75651 Paris, France

[2] Massachusetts Gen Hosp, Partners AIDS Res Ctr, Howard Hughes Med Inst, Boston, MA 02129 USA

[3] Harvard Univ, Sch Med, Div AIDS, Boston, MA 02129 USA

来源：

NATURE REVIEWS IMMUNOLOGY | 2003年 / 3卷 / 06期

关键词：

D O I：

10.1038/nri1107

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The successes of anti-retroviral treatments against HIV are limited today by the cost and toxicity of lifelong administration. An innovative therapeutic strategy has been proposed to boost the immune system of infected patients with HIV vaccines and to help limit the use of anti-retroviral treatments. This perspective article reviews the crucial questions raised by such a strategy and the main international efforts that are already set up to provide rapid answers - in particular, a not-for-profit international network that is dedicated to the development of therapeutic immunization programmes against HIV.

引用

页码：503 / 508

页数：6

共 39 条

[11] Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy [J].

Finzi, D ;

Blankson, J ;

Siliciano, JD ;

Margolick, JB ;

Chadwick, K ;

Pierson, T ;

Smith, K ;

Lisziewicz, J ;

Lori, F ;

Flexner, C ;

Quinn, TC ;

Chaisson, RE ;

Rosenberg, E ;

Walker, B ;

Gange, S ;

Gallant, J ;

Siliciano, RF .

NATURE MEDICINE, 1999, 5 (05) :512-517

[12]

GOH LE, 2000, NAT MED, V11, P1194

[13]

Harrer T, 1996, J IMMUNOL, V156, P2616

[14] Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques [J].

Hel, Z ;

Venzon, D ;

Poudyal, M ;

Tsai, WP ;

Giuliani, L ;

Woodward, R ;

Chougnet, C ;

Shearer, G ;

Altman, JD ;

Watkins, D ;

Bischofberger, N ;

Abimiku, A ;

Markham, P ;

Tartaglia, J ;

Franchini, G .

NATURE MEDICINE, 2000, 6 (10) :1140-1146

[15] Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy [J].

Jin, X ;

Ramanathan, M ;

Barsoum, S ;

Deschenes, GR ;

Ba, L ;

Binley, J ;

Schiller, D ;

Bauer, DE ;

Chen, DC ;

Hurley, A ;

Gebuhrer, L ;

El Habib, R ;

Caudrelier, P ;

Klein, M ;

Zhang, LQ ;

Ho, DD ;

Markowitz, M .

JOURNAL OF VIROLOGY, 2002, 76 (05) :2206-2216

[16] Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy [J].

Jouan, M ;

Savès, M ;

Tubiana, R ;

Carcelain, G ;

Cassoux, N ;

Aubron-Olivier, C ;

Fillet, AM ;

Nciri, M ;

Sénéchal, B ;

Chêne, G ;

Tural, C ;

Lasry, S ;

Autran, B ;

Katlama, C .

AIDS, 2001, 15 (01) :23-31

[17] TEMPORAL ASSOCIATION OF CELLULAR IMMUNE-RESPONSES WITH THE INITIAL CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SYNDROME [J].

KOUP, RA ;

SAFRIT, JT ;

CAO, YZ ;

ANDREWS, CA ;

MCLEOD, G ;

BORKOWSKY, W ;

FARTHING, C ;

HO, DD .

JOURNAL OF VIROLOGY, 1994, 68 (07) :4650-4655

[18]

LEGARFF M, 2003, 10 C RETR OPP INF BO

[19]

LEVY Y, 2003, 10 C RETR OPP INF BO

[20] Therapeutic dendritic-cell vaccine for simian AIDS [J].

Lu, W ;

Wu, XX ;

Lu, YZ ;

Guo, WZ ;

Andrieu, JM .

NATURE MEDICINE, 2003, 9 (01) :27-32

← 1 2 3 4 →